Linked Life Data

10754294

Source:http://linkedlifedata.com/resource/pubmed/id/10754294

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2000-5-9
pubmed:abstractText
CK beta-11 chemoattracts T cells, B cells, dendritic cells, macrophage progenitors, and NK cells and facilitates dendritic cell and T cell interactions in secondary lymphoid tissues. We hypothesized that expression of CK beta-11 in tumor cells may generate antitumor immunity through these interactions. After transduction with the retroviral vector L(CK beta 11)SN, the murine breast cancer cell line C3L5 (C3L5-CK beta 11) showed expression of retroviral mRNA by Northern analysis and production of functional CK beta-11 by chemotaxis of human NK cells to C3L5-CK beta 11 supernatant. Only 10% of mice injected with C3L5-CK beta 11 developed tumors, compared with 100% of mice injected with a transduced control C3L5 line (C3L5-G1N). Importantly, the in vitro growth characteristics of the CK beta-11-transduced cell line were unaffected, suggesting the difference in growth in vivo was a result of chemokine production. Vaccination with C3L5-CK beta 11 partially protected animals from parental C3L5 challenge. Immunodepletion with anti-asialo-GM1 or anti-CD4 during C3L5-CK beta 11 vaccination significantly reduced CK beta-11 antitumor activity compared with control and anti-CD8-treated groups. Splenocytes from NK-depleted animals transferred the acquired immunity generated with C3L5-CK beta 11 vaccination, while splenocytes from the CD4-depleted animals did not. These results indicate, for the first time, that expression of CK beta-11 in a breast cancer cell line mediates rejection of the transduced tumor through a mechanism involving NK and CD4+ cells. Furthermore, CK beta-11-transduced tumor cells generate long-term antitumor immunity that requires CD4+ cells. These studies demonstrate the potential role of CK beta-11 as an adjuvant in stimulating antitumor responses.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
164
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4025-31
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:10754294-Animals, pubmed-meshheading:10754294-Cancer Vaccines, pubmed-meshheading:10754294-Chemokine CCL19, pubmed-meshheading:10754294-Chemokines, CC, pubmed-meshheading:10754294-Female, pubmed-meshheading:10754294-Gene Transfer Techniques, pubmed-meshheading:10754294-Genetic Vectors, pubmed-meshheading:10754294-Graft Rejection, pubmed-meshheading:10754294-Humans, pubmed-meshheading:10754294-Immune Sera, pubmed-meshheading:10754294-Injections, Intraperitoneal, pubmed-meshheading:10754294-Injections, Subcutaneous, pubmed-meshheading:10754294-Killer Cells, Natural, pubmed-meshheading:10754294-Lymphocyte Depletion, pubmed-meshheading:10754294-Lymphocyte Subsets, pubmed-meshheading:10754294-Lymphocyte Transfusion, pubmed-meshheading:10754294-Mammary Neoplasms, Experimental, pubmed-meshheading:10754294-Mice, pubmed-meshheading:10754294-Mice, Inbred C3H, pubmed-meshheading:10754294-Neoplasm Transplantation, pubmed-meshheading:10754294-Spleen, pubmed-meshheading:10754294-Tumor Cells, Cultured
pubmed:year
2000
pubmed:articleTitle
The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells.
pubmed:affiliation
Departments ofMicrobiology/Immunology and Medicine (Hematology/Oncology), and Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA. stephen_braun@hms.harvard.edu
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't